Frontiers in Immunology (Jun 2023)
TMEM123 a key player in immune surveillance of colorectal cancer
- Elisa Pesce,
- Chiara Cordiglieri,
- Mauro Bombaci,
- Serenella Eppenberger-Castori,
- Stefania Oliveto,
- Cristina Manara,
- Mariacristina Crosti,
- Caner Ercan,
- Mairene Coto,
- Andrea Gobbini,
- Susanna Campagnoli,
- Tiziano Donnarumma,
- Manuele Martinelli,
- Valeria Bevilacqua,
- Elisa De Camilli,
- Paola Gruarin,
- Maria L. Sarnicola,
- Elisa Cassinotti,
- Ludovica Baldari,
- Giuseppe Viale,
- Giuseppe Viale,
- Stefano Biffo,
- Stefano Biffo,
- Sergio Abrignani,
- Sergio Abrignani,
- Luigi M. Terracciano,
- Luigi M. Terracciano,
- Renata Grifantini,
- Renata Grifantini
Affiliations
- Elisa Pesce
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Chiara Cordiglieri
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Mauro Bombaci
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Serenella Eppenberger-Castori
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
- Stefania Oliveto
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Cristina Manara
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Mariacristina Crosti
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Caner Ercan
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
- Mairene Coto
- Institute of Pathology, University Hospital Basel, Basel, Switzerland
- Andrea Gobbini
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Susanna Campagnoli
- CheckmAb Srl, Milan, Italy
- Tiziano Donnarumma
- CheckmAb Srl, Milan, Italy
- Manuele Martinelli
- CheckmAb Srl, Milan, Italy
- Valeria Bevilacqua
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Elisa De Camilli
- Department of Pathology, European Institute of Oncology, Milan, Italy
- Paola Gruarin
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Maria L. Sarnicola
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Elisa Cassinotti
- Department of Surgery, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
- Ludovica Baldari
- Department of Surgery, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy
- Giuseppe Viale
- Department of Pathology, European Institute of Oncology, Milan, Italy
- Giuseppe Viale
- Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy
- Stefano Biffo
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Stefano Biffo
- Department of Biosciences, Università degli Studi di Milano, Milan, Italy
- Sergio Abrignani
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Sergio Abrignani
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
- Luigi M. Terracciano
- IRCCS Humanitas Research Hospital, Rozzano, Italy
- Luigi M. Terracciano
- 0Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy
- Renata Grifantini
- Istituto Nazionale Genetica Molecolare (INGM), Padiglione Romeo ed Enrica Invernizzi, IRCCS Ospedale Maggiore Policlinico, Milan, Italy
- Renata Grifantini
- CheckmAb Srl, Milan, Italy
- DOI
- https://doi.org/10.3389/fimmu.2023.1194087
- Journal volume & issue
-
Vol. 14
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-associated death. In the tumor site, the interplay between effector immune cells and cancer cells determines the balance between tumor elimination or outgrowth. We discovered that the protein TMEM123 is over-expressed in tumour-infiltrating CD4 and CD8 T lymphocytes and it contributes to their effector phenotype. The presence of infiltrating TMEM123+ CD8+ T cells is associated with better overall and metastasis-free survival. TMEM123 localizes in the protrusions of infiltrating T cells, it contributes to lymphocyte migration and cytoskeleton organization. TMEM123 silencing modulates the underlying signaling pathways dependent on the cytoskeletal regulator WASP and the Arp2/3 actin nucleation complex, which are required for synaptic force exertion. Using tumoroid-lymphocyte co-culture assays, we found that lymphocytes form clusters through TMEM123, anchoring to cancer cells and contributing to their killing. We propose an active role for TMEM123 in the anti-cancer activity of T cells within tumour microenvironment.
Keywords
- colorectal cancer
- tumor microenvironment
- tumor-infiltrating lymphocytes
- TMEM123
- cytoskeleton organization
- cell adhesion